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Abstract Although family history is a major risk factor for
colorectal cancer (CRC) a genetic diagnosis cannot be
obtained in over 50 % of familial cases when screened for
known CRC cancer susceptibility genes. The genetics of
undefined-familial CRC is complex and recent studies have
implied additional clinically actionable mutations for
CRC in susceptibility genes for other cancers. To clarify
the contribution of non-CRC susceptibility genes to unde-
fined-familial CRC we conducted a mutational screen of
114 cancer susceptibility genes in 847 patients with early-
onset undefined-familial CRC and 1609 controls by ana-
lysing high-coverage exome sequencing data. We imple-
mented American College of Medical Genetics and
Genomics standards and guidelines for assigning
pathogenicity to variants. Globally across all 114 cancer
susceptibility genes no statistically significant enrichment
of likely pathogenic variants was shown (6.7 % cases
57/847, 5.3 % controls 85/1609; P = 0.15). Moreover
there was no significant enrichment of mutations in genes
such as TP53 or BRCA2 which have been proposed for
clinical testing in CRC. In conclusion, while we identified
genes that may be considered interesting candidates as
determinants of CRC risk warranting further research, there
is currently scant evidence to support a role for genes other
than those responsible for established CRC syndromes in
the clinical management of familial CRC.
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Introduction
Family history is a major risk factor for colorectal cancer
(CRC) with around 15 % of patients reporting having a
first-degree relative affected with CRC [1]. Understanding
the genetic basis of familial CRC risk is clinically relevant
for discriminating between high- and low-risk groups;
important not only in defining screening requirements and
genetic counselling but increasingly for optimising
chemotherapy [2].
Although Lynch syndrome and familial adenomatous
polyposis (FAP), caused by inherited germline mismatch
repair (MMR) and APC gene mutations respectively,
contribute significantly to CRC a genetic diagnosis cannot
be obtained in over 50 % of familial cases [3]. While
Amsterdam positive families negative for MMR mutations
have been labelled as Familial CRC Type X [4] this is
merely a descriptive definition and the genetic basis of all
forms of undefined-familial CRC is likely to be complex.
Many cancer susceptibility genes are pleiotropic (i.e.
influence multiple types of malignancies) [5] and epi-
demiological studies have reported moderate increases in
risk of CRC associated with a number of cancer suscepti-
bility genes. It has been recently suggested that mutations
in cancer susceptibility genes not normally considered
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primarily as determinants of CRC risk such as BRCA2 [6]
and TP53 [7] contribute significantly to CRC and are of
clinical utility.
To clarify the contribution of non-CRC cancer suscep-
tibility genes to undefined-familial CRC we report a
comprehensive mutational screen of 114 such genes in 847
patients systematically ascertained with early-onset unde-
fined-familial CRC.
Materials and methods
Cancer susceptibility genes evaluated
We evaluated a set of 114 well established cancer sus-
ceptibility genes in which rare mutations have been docu-
mented to confer high or moderate risk of cancer [5].
Subjects, sequencing and quality control
We report data on 857 unrelated cases of undefined-fa-
milial CRC that were negative for a mutation in a known
cancer susceptibility genes for CRC. Specifically, there
was no evidence of a likely pathogenic mutation in one of
the known CRC genes—APC, MLH1, SMAD4, BMPR1A,
MUTYH, MSH2, MSH6, PMS2, POLE or POLD1. The
cases were derived from a previous whole exome
sequencing (WES) gene discovery project based on 1028
familial cases (C1 first-degree relative) with early-onset
CRC (B55 years) ascertained through the UK National
Study of Colorectal Cancer Genetics [8, 9]. To determine
the population prevalence of cancer susceptibility gene
mutations we analysed WES data on 1644 healthy indi-
viduals (with no personal history of malignancy) from the
UK 1958 Birth cohort (58BC [10]—974 from the ICR1000
dataset (EGAD00001001021) [11] and an additional 670
individuals all sequenced at The Institute of Cancer
Research as per cases.
Full details of sample ascertainment, sequencing pipe-
line for these samples have been reported [9]. Briefly,
samples with non-northern European ancestry, high levels
of heterozygosity, sex discrepancy, poor call rate and
contamination were excluded. We considered only
canonical transcripts and for each variant, assumed the
most deleterious predicted effect for each Ensembl tran-
script according to Variant Effect Predictor [12]. To
identify false positives we adopted an automated approach
imposing: GQ C 30, for a heterozygous call an alternate
depth C3 and v2\ 10.83 (i.e. P[ 0.0001) for the
observed versus expected distribution of alternate/refer-
ence alleles (alt-ref-ratio), UCSC alignability (100 bp
window size) = 1, not in simple repeat, Hardy–Weinberg
Equilibrium (HWE) test (P[ 1.0 9 10-8) in cases and
controls and an overall call rate C75 % in both cases and
controls. We evaluated the fidelity of sequencing in 1332
samples which had also been genotyped using Illumina
HumanExome-12v1_A Beadchip arrays (Illumina, San
Diego, CA, USA). Specificity and sensitivity of across all
alleles with MAF\ 0.05 was [99.99 % and 78.4 %
respectively for filtered variants.
Interpretation of variant pathogenicity
We implemented the American College of Medical
Genetics and Genomics (ACMG) standards and guidelines
for determining the pathogenicity of variants [13]. ACMG
definitions are contingent on the population frequencies of
variants. Here we utilised frequency information from the
non-Finnish European Exome Aggregation Consortium
(NFE-ExAC), excluding The Cancer Genome Atlas
(TCGA) samples when appropriate (nonTCGA-NFE-
ExAC). For assigning pathogenicity of novel missense
mutations ACMG requires the rate of benign missense
variation to be determined in genes and functional domains
(PM1 and PP2). ACMG defines mutations as benign if seen
in[5 % of the population (BA1). We exploited this defi-
nition, counting the frequency of missense mutations in our
dataset with NFE-ExAC frequency[5 %, to quantify the
rate of benign missense variation. When normalised for
protein length, none of the cancer susceptibility genes
evaluated in this study fell outside of two standard devia-
tions from the average mutational rate of 1.2 mutations per
1000 amino acids (\6.6). ACMG also requires novel
mutations to conform to established mechanisms of action
for each gene, therefore established mechanisms were
determined by mining pathogenic/likely pathogenic (P/LP)
mutations for any disease in ClinVar (NFE-ExAC\ 1 %)
and combined with annotations from the expertly curated
Cosmic Gene Census [14] and where available relevant
literature.
Definition of pathogenic/likely pathogenic (P/LP) vari-
ants: We required all variants to be rare with a nonTCGA-
NFE-ExAC frequency \0.01 % for dominantly acting
genes or \0.5 % for genes with evidence of recessive
action. We automatically included variants marked as
‘‘pathogenic’’ or ‘‘likely pathogenic’’ in ClinVar which met
the above frequency conditions and where ClinVar anno-
tations were not conflicted. Novel loss of function (LOF)
and splice site variants met the criteria for likely patho-
genic only when the mechanism of action (e.g. splice site)
was established for that gene. Only canonical transcripts
were considered. LOF variants at the extreme 30 end of the
gene were excluded from analysis (final coding 5 % [15]).
Missense mutations were included where the same amino
acid change was observed as a previously established P/LP
variant regardless of nucleotide change.
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Definition of novel likely pathogenic (LP) missense set:
We also defined a set of novel (not documented in Clinvar)
likely pathogenic missense mutations requiring, in addition
to the criteria outlined above: (1) a consensus that the
mutation is deleterious in a minimum of 6/8 computational
tools calculated via ANNOVAR [16] (satisfying PP3 cri-
teria; SIFT, Polyphen-pp2hvar, LRT, MutationTaster,
MutationAssessor, FATHMM, RadialSVM and LR) (2)
that the variant is in a gene with a low rate of benign
missense variation (PP2) (3) located in PFAM domain with
documented P/LP variants with no benign variation (PM1)
and (4) for dominantly acting variants only: absent from
the nonTCGA-NFE-ExAC population (PM2).
P values, where reported, were calculated using a two-
sided Fisher’s exact test in R [17].
Results and discussion
Overall 6.7 % of the undefined-familial CRC cases (57/
847) and 5.3 % of the controls (85/1609) were identified as
being a carrier of a P/LP mutation in one of the 114 cancer
susceptibility genes surveyed (Table 1; Supplementary
Table 2). Globally the difference is not statistically sig-
nificant implying that pleiotropic effects across cancer
susceptibility genes are not widespread with respect to
CRC and certainly rare and/or not highly penetrant. Fur-
thermore, after correcting for multiple testing, no individ-
ual gene was significantly mutated in undefined-familial
CRC cases. This does not preclude the possibility that some
of the mutations we have identified are causal, but does
place bounds on their prevalence and clinical utility.
Three cases (0.3 %) were identified as being carriers of
P/LP mutations in the folliculin gene FLCN: a stop gain
(p.Ser386Ter), splice donor (c.1432 ? 1G[A) and a fra-
meshift variant (p.Glu297AlafsTer25) catalogued by
ClinVar as pathogenic (Table 2). These mutations are
extremely rare with only the frameshift variant present in a
single sample in nonTCGA-NFE-ExAC. FLCN is a highly
conserved gene and recent computational methods have
predicted FLCN to be intolerant to LOF variants (analysis
of protein-coding genetic variation in 60,706 humans, Lek
et al. preprint). While mutations in FLCN cause Birt-Hogg-
Dube syndrome (BHD) [18], and are seen in 5 % of
familial renal cell cancer patients suggesting a role in
cancer predisposition [19], none of the gene carriers we
identified had a personal or family history of renal cancer.
Although recent data has been conflicted as to whether
there is an increased incidence of CRC associated with
BHD, Nahorski et al. [20] have reported FLCN deactiva-
tion contributes to colorectal tumourigenesis with somatic
frameshift mutations being identifiable in 23 % of
microsatellite instable CRC.
A further three cases had P/LP frameshift mutations in
the nucleotide excision repair (NER) gene ERCC3; two
cases with p.Gln586ArgfsTer25 and a single sample with
p.Asp474GlufsTer2 (Table 2). We observe a LP mutation
in a single control: p.Arg109Ter. ERCC3 forms a subunit
of the basal transcription factor 2 (TFIIH, Table 1) and is
associated with Xeroderma pigmentosum B [21], Cock-
ayne’s syndrome [22] and trichothiodystrophy [23]. A
variant in the related NER protein ERCC6 was recently
suggested as a candidate for familial CRC following exome
sequencing with functional data supporting a reduction in
Table 1 Case/control statistics for cancer susceptibility genes
Gene P/LP variant set P Novel LP missense set
Case Control Case Control
FLCN 3 0 0.04 0 0
ERCC3 3 1 0.12 0 0
BLM 3 1 0.12 1 0
BRCA2 5 3 0.14 1 0
ERCC4 4 2 0.19 0 0
BRIP1 6 5 0.21 0 1
RAD51D 2 1 0.28 0 0
ERCC5 1 0 0.35 1 0
POLH 1 0 0.35 6 6
MEN1 1 0 0.35 1 1
DDB2 1 0 0.35 0 0
TGFBR1 1 0 0.35 0 0
CYLD 1 0 0.35 0 0
BUB1B 1 0 0.35 0 0
NF1 1 0 0.35 0 0
TP53 1 0 0.35 0 1
EXT2 1 0 0.35 0 2
BRCA1 4 5 0.51 0 0
NBN 2 2 0.61 0 0
CHEK2 1 4 0.66 1 0
FAH 1 5 0.67 3 4
ATM 4 8 1 0 0
RECQL4 3 6 1 0 0
FANCC 2 4 1 0 0
ERCC2 2 3 1 0 0
COL7A1 1 3 1 13 22
SERPINA1 1 2 1 0 1
SLC25A13 1 2 1 0 0
TRIM37 1 1 1 0 0
FANCG 1 1 1 0 0
PALB2 1 1 1 0 0
Any gene with at least one case P/LP mutation is included and ranked
by Fisher’s exact P value. Some individuals carry variants in more
than one gene
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capacity for repairing DNA double strand breaks [24]. In
transcription coupled (TC)-NER, blockage of transcribing
RNA Polymerase II (RNA-Pol II) on the damaged DNA
template is thought to initiate the repair reaction in a pro-
cess that requires ERCC6 in combination with ERCC2
(TFIIH subunit), ERCC3 (TFIIH subunit), ERCC1-ERCC4
Table 2 Summary information for the mutations observed in the cancer susceptibility genes: FLCN, TC-NER genes, BLM and BRCA1/2
Gene cDNA change Protein change Consequence Case Control ExACa count ClinVar
FLCN c.1432 ? 1G[A SD 1 0 0 –
c.1157C[G p.Ser386Ter SG 1 0 0 –
c.890_893delAAAG p.Glu297AlafsTer25 FS 1 0 1 P
ERCC2 c.2138G[A p.Gly713Asp M 0 1 0 P
c.1827delC p.Phe610LeufsTer99 FS 1 0 1 –
c.1381C[G p.Leu461Val M 1 2 31 P
ERCC3 c.1757delA p.Gln586ArgfsTer25 FS 2 0 18 –
c.1421dupA p.Asp474GlufsTer2 FS 1 0 6 –
c.325C[T p.Arg109Ter SG 0 1 42 –
ERCC4 c.458G[A p.Arg153His M 1 0 1 P
c.1399delA p.Arg468AspfsTer25 FS 1e 0 0 –
c.2395C[T p.Arg799Trp M 2 2 35 P
ERCC5 c.274A[Tb p.Arg92Trp M 1 0 1 –
c.1207_1208insTGTGTGC p.Gly406ValfsTer5 FS 1 0 0 –
ERCC6c c.2167C[T p.Gln723Ter SG 2 1 4 P
c.1958A[Gb p.Asn653Ser M 1 0 0 –
c.1780G[Ab p.Val594Met M 0 1 0 –
c.2093dupG p.Thr699HisfsTer61 FS 1 0 0 –
XPA c.338_339delTG p.Met113ArgfsTer9 FS 0 1 1 –
BLM c.1081_1082delTG p.Cys361Ter FS 1 0 0 –
c.1933C[T p.Gln645Ter SG 1 0 4 –
c.2422C[Tb p.Arg808Cys M 1 0 7 –
c.2695C[T p.Arg899Ter SG 1 1 6 LP;P
BRCA1 c.5186C[A p.Ala1729Glu M 1 0 2 P
c.5158C[T p.Arg1720Trp M 0 1 0 P
c.3756_3759delGTCT p.Ser1253ArgfsTer10 FS 2 1 0 LP;P
c.3228_3229delAG p.Gly1077AlafsTer8 FS 1d 0 0 LP;P
c.2194G[T p.Glu732Ter SG 0 1 0 P
c.1849_1850delAC p.Thr617GlnfsTer7 FS 0 1 0 –
c.246delT p.Val83LeufsTer5 FS 0 1 0 –
BRCA2 c.3158T[G p.Leu1053Ter SG 0 1 0 P
c.3680_3681delTG p.Leu1227GlnfsTer5 FS 1 0 0 P
c.3689delC p.Ser1230LeufsTer9 FS 1d 0 0 P
c.5682C[A p.Tyr1894Ter SG 1 0 0 P
c.5946delT p.Ser1982ArgfsTer22 FS 0 1 21 P;RF
c.6275_6276delTT p.Leu2092ProfsTer7 FS 1 0 1 P
c.6535_6536insA p.Val2179AspfsTer10 FS 1 0 1 –
c.7933A[Gb p.Arg2645Gly M 1 0 0 –
c.9054_9055delTA p.Ser3018ArgfsTer3 FS 0 1 0 P
Conseqeuence: SD splice donor, SG stop gain, FS frameshift, M missense. Clinvar: P pathogenic, LP likely pathogenic, RF risk factor
a NonTCGA-NFE-ExAC count
b LP Missense variant
c ERCC6 not in cancer susceptibility gene set but included for information
d Case has FS mutations affecting BRCA1 and BRCA2
e Case has SG in PALB2 (Tyr1183Ter; Exac = 1) although Clinvar pathogenic affects only final 1 % of protein
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(XPF), ERCC5 (XPG), ERCC8 (CSA) and XPA. We
observed P/LP mutations in six of these genes in total
identifying 13 in cases and eight in controls (Table 2, 1.5
vs 0.5 %, P = 0.011; 15 vs 9 including LP missense,
P = 0.008). We identify two patients with first degree
relatives with malignant melanoma of the skin (ERCC4
p.Arg468AspfsTer25 and ERCC6 p.Thr699HisfsTer61).
With the exception of ERCC6 thus far mutations of the
NER genes have not been implicated as risk factors for
CRC. It is however noteworthy that ERRC1 expression has
been shown to be reduced by 84–100 % in CRC [25, 26].
Three cases and one control were found to harbour rare
novel LOF mutations in the recessively acting Bloom
syndrome gene BLM (Table 2): one case with the frame-
shift mutation p.Cys361Ter, another with the stop gain
mutation p.Gln645Ter and an additional case and control
both having the stop gain mutation p.Arg899Ter cata-
logued as pathogenic and likely pathogenic in ClinVar for
hereditary cancer predisposition syndrome and Bloom’s
respectively. An additional rare missense mutation meeting
ACMG guidelines for likely pathogenic variants was
identified in the cases (p.Arg808Cys, no such variants in
controls). While the family histories of these samples are
varied, only one Bloom’s related malignancy (myeloma)
was reported in the mother of an affected individual where
the father was diagnosed with CRC. While our results
could be considered to support a possible role for BLM in
CRC risk, we do not observe as high a frequency of P/LP
mutations as a recent study which found enrichment in
early-onset CRC patients with deleterious BLM mutations
(1.6 % of patients and 0.02 % controls [27]).
With respect to BRCA1/2mutations we observed a range
of mutation types including ten frameshift (6 cases, 5
controls) three stop gained (1 case, 2 controls) and two
missense (1 case, 1 control) with the majority of variants
(12/15) documented as pathogenic by ClinVar (0.9 % vs
0.5 %, P = 0.20, Table 2). Whilst 5/8 of cases had a
family history of breast and/or ovarian cancer, in three
cases CRC was observed in the father with the BRCA
associated cancer observed in the mother. Of these three
patients, one carried BRCA1:p.Gly1077AlafsTer8 and
BRCA2:p.Ser1230LeufsTer9, both catalogued as patho-
genic in ClinVar and absent in nonTCGA-NFE-ExAC.
Of the other cancer susceptibility genes recently impli-
cated in CRC, includingWRN [24], SMARCA4 [28], AXIN2
[29, 30] and TP53 [7], we only identified a single case with
a mutation: TP53 p.Glu68Ter. This case, a male aged 48 at
diagnosis, had no personal history of other cancers or a
family history of any Li-Fraumeni associated malignancy.
Our results do not support the recent assertion of a clini-
cally important role for TP53 in CRC [7]. It is however
noteworthy that the TP53 mutations reported by Yurgelun
et al. [7] were all (bar one) predicted benign missense
changes and no reference to gene burden in a comparison
with controls was performed.
Conclusion
In a large number of patients with familial CRC no alter-
ation in any known CRC susceptibility gene can be iden-
tified. An explanation of their susceptibility is a priority in
order to offer accurate genetic counselling and determine
appropriate screening and/or treatment. Many cancer sus-
ceptibility genes have pleiotropic effects increasing the risk
of a spectrum of cancers to varying degrees [5]. Hence the
suggestion that non-CRC cancer susceptibility genes con-
tribute to familial CRC is an attractive proposition.
However the risks for the minor type of cancer are in
general modest with, for example, studies suggesting a
20–60 % increase in risk associated with BRCA2 mutations
and cancers outside of breast and ovarian [6]. This is in
contrast to mutations in genes such as TP53 that are typi-
fied by a constellation of cancers in the same family. In
addition to the phenotypic variability associated with the
classical dominantly acting cancer susceptibility genes
there is evidence of increased cancer risk in carriers of
recessive cancer syndrome mutations; exemplified by
heterozygous ATM mutations associated with a two-fold
elevated breast cancer risk [31]. The magnitude of these
effects are therefore insufficient to result in families seg-
regating only the minor tumour. While this means cancer
susceptibility gene pleiotropism will not significantly
account for undefined-familial CRC families per se such
effects have the potential to impact on the overall burden of
CRC.
Even accepting the potential inflation introduced
through using cancer free controls, when considering all
114 cancer susceptibility genes, we did not observe a sig-
nificant difference in frequency of pathogenic mutations
between cases and controls. Although only nominally sig-
nificant we did identify P/LP mutations in a number of
interesting candidate genes including FLCN, BLM, ERCC-
genes and BRCA1/2 as possible determinants of CRC risk.
Accurately ascribing pathogenicity to variants is a key
challenge in interpreting sequencing data and we must be
cognisant of variation that is disregarded or missing such as
splice region or copy number variation. While our estimated
frequency of P/LP mutations broadly fits with epidemio-
logical estimates, it is likely that some of the cancer sus-
ceptibility genes included in this analysis are able to tolerate
apparent LOF variants. Indeed we observed some over-
representation of BRIP1 P/LP mutations amongst cases (6
cases, 5 controls) and a study by Seal et al. [32] had reported
rare truncating mutations in BRIP1 with increased breast
cancer risk. However a large replication effort of the most
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common truncating variant found no evidence to support an
association between BRIP1 with breast cancer [33].
While we identified genes that may be considered
interesting candidates for further research our inability to
replicate other recent studies highlights the caution required
when interpreting such research. Additional much larger
data sets, familial studies and/or functional follow up would
be required to confirm the role and scope of cancer sus-
ceptibility genes outside of those already clearly established
with heritable CRC syndromes. However, compared to
contemporaneous research efforts, a major strength of our
study is its size enabling us to explore the maximum likely
impact of non-CRC cancer susceptibility genes to unde-
fined-familial CRC. In conclusion there is currently scant
evidence to support a role for genes other than those
responsible for established CRC syndromes in the clinical
management of CRC patients. While testing for such genes
has no immediate clinical utility, the accumulation of such
data, in combination with functional studies and familial
segregation, has the potential to robustly determine the role
of these genes in CRC aetiology. Furthermore, as the cost of
high throughput sequencing continues to reduce, such
efforts may become economically justifiable.
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